The piece entitled “VIVEbiotech: A Lentiviral Vector Specialist Bridging the Gap Between R&D and Commercialisation” has been included in their September/October issue. It has not only been featured as a double-page spread, but the piece has also been published as a stand-alone article on their site.

The article talks about the company’s expertise meeting the surging demand in the cell and gene therapy market, driven by the growing need for outsourced lentiviral vector supply. Moreover, it emphasizes VIVEbiotech´s technical proficiency ensuring efficient and compliant vector manufacturing, and remarks how it is the sole European GMP CDMO specialized in lentiviral vectors, playing a critical role in bridging the gap between research and commercialization in the expanding CGT field.

You can read the full article here: